Categories AlphaGraphs, Earnings, Finance, LATEST
Bank of New York Mellon beats Q2 earnings estimates; revenues in-line
The Bank of New York Mellon Corporation (NYSE: BK) topped analysts’ forecasts on earnings for the second quarter of 2019 while revenues matched expectations. The stock was up 0.90% in premarket hours on Wednesday.
Total revenue decreased 5% to $3.9 billion from last year, reflecting lower fee and net interest revenues, but the results were in line with estimates.
Net income fell 8% year-over-year to $969 million while EPS dropped 2% to $1.01. Analysts had forecast EPS of $0.95.
Fee revenue decreased 3%, mainly due to cumulative AUM outflows, negative impacts from a strong US dollar and lower foreign exchange and securities lending revenue. Net interest revenue declined 12%, hurt by higher deposit and funding costs and the impact of hedging activities.
In the Investment Services business, total revenues fell 3%. Within this business, the company saw revenue growth on a year-over-year basis in most of its divisions except for Asset Servicing and Treasury Services. The decreases in these two divisions were mainly due to lower net interest revenue.
In the Investment Management business, total revenues decreased 10%. Within the segment, revenues declined in both the Asset Management and Wealth Management divisions year-over-year due to various factors including impacts from divestitures and hedging activities and lower net interest revenue.
Assets under custody and/or administration (AUC/A) and assets under management (AUM) both saw single-digit increases, helped by higher market values and net new business.
In a separate release, the company declared a quarterly common stock dividend of $0.31 per share, payable on August 9, 2019 to shareholders of record on July 29, 2019.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on